NCT05480579View on ClinicalTrials.gov

A Study of IBI311 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 10, 2022

Primary Completion Date

November 23, 2022

Study Completion Date

January 19, 2023

Conditions
Healthy
Interventions
BIOLOGICAL

placebo

Dose4 placebo of single IV injection

BIOLOGICAL

IBI311

Dose2 IBI311 of single IV injection

BIOLOGICAL

IBI311

Dose4 IBI311 of single IV injection

BIOLOGICAL

placebo

Dose3 placebo of single IV injection

BIOLOGICAL

placebo

Dose1 placebo of single IV injection

BIOLOGICAL

IBI311

Dose1 IBI311 of single IV injection

BIOLOGICAL

IBI311

Dose 3 IBI311 of single IV injection

BIOLOGICAL

placebo

Dose2 placebo of single IV injection

Trial Locations (1)

200041

Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY